CN104367874A - 一种治疗猪高热病的中药组合物 - Google Patents
一种治疗猪高热病的中药组合物 Download PDFInfo
- Publication number
- CN104367874A CN104367874A CN201410658595.XA CN201410658595A CN104367874A CN 104367874 A CN104367874 A CN 104367874A CN 201410658595 A CN201410658595 A CN 201410658595A CN 104367874 A CN104367874 A CN 104367874A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicinal liquid
- radix
- radix astragali
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 241000282898 Sus scrofa Species 0.000 title abstract description 55
- 208000021760 high fever Diseases 0.000 title abstract 6
- 239000003814 drug Substances 0.000 claims abstract description 135
- 229940079593 drug Drugs 0.000 claims abstract description 32
- 239000007788 liquid Substances 0.000 claims description 113
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 59
- 239000009636 Huang Qi Substances 0.000 claims description 51
- 238000011282 treatment Methods 0.000 claims description 50
- 206010020843 Hyperthermia Diseases 0.000 claims description 42
- 230000036031 hyperthermia Effects 0.000 claims description 42
- 239000000463 material Substances 0.000 claims description 26
- 238000009835 boiling Methods 0.000 claims description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 14
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 13
- 241000628997 Flos Species 0.000 claims description 12
- 239000010231 banlangen Substances 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 239000003002 pH adjusting agent Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 24
- 239000002994 raw material Substances 0.000 abstract description 7
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract description 5
- 241001061264 Astragalus Species 0.000 abstract description 2
- 239000003242 anti bacterial agent Substances 0.000 abstract description 2
- 229940088710 antibiotic agent Drugs 0.000 abstract description 2
- 235000006533 astragalus Nutrition 0.000 abstract description 2
- 239000003640 drug residue Substances 0.000 abstract description 2
- 210000004233 talus Anatomy 0.000 abstract description 2
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 241000037740 Coptis chinensis Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 241000334160 Isatis Species 0.000 abstract 1
- 240000003915 Lophatherum gracile Species 0.000 abstract 1
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 abstract 1
- 241001121987 Scrophularia ningpoensis Species 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 229910052602 gypsum Inorganic materials 0.000 abstract 1
- 239000010440 gypsum Substances 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 235000015277 pork Nutrition 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 230000000052 comparative effect Effects 0.000 description 16
- 206010020741 Hyperpyrexia Diseases 0.000 description 13
- 230000036760 body temperature Effects 0.000 description 12
- 230000036528 appetite Effects 0.000 description 11
- 235000019789 appetite Nutrition 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 229930182470 glycoside Natural products 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- -1 berberine Chemical class 0.000 description 9
- 230000002265 prevention Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- VQMZQKBLIKANMK-IKFJEIPGSA-N (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S,16S,18R)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol (2S,3R,4S,5S,6R)-2-[(2R,3S,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(1S,2R,4R,5'S,6R,7R,8S,9S,12R,13S,16R,18S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound C[C@H]1CC[C@@]2([C@@H]([C@@H]3[C@H](O2)C[C@H]4[C@@]3(CC[C@@H]5[C@@H]4CC[C@@H]6[C@@]5(CC[C@H](C6)O[C@H]7[C@H]([C@H]([C@H]([C@H](O7)CO)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C)C)C)OC1.C[C@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@H]6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C)C)C)OC1 VQMZQKBLIKANMK-IKFJEIPGSA-N 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 235000001727 glucose Nutrition 0.000 description 6
- 150000002338 glycosides Chemical class 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000003440 toxic substance Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 229930182490 saponin Natural products 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- APTNOIWSCDBIAS-UHFFFAOYSA-N 5,10,11-trihydroxy-9,9-bis(hydroxymethyl)-2,2,6a,6b,12a-pentamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound C1C(O)C(O)C(CO)(CO)C2CCC3(C)C4(C)CC(O)C5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C APTNOIWSCDBIAS-UHFFFAOYSA-N 0.000 description 4
- 208000003322 Coinfection Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- QMQIQBOGXYYATH-IDABPMKMSA-N Ruscogenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)[C@H](O)C[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 QMQIQBOGXYYATH-IDABPMKMSA-N 0.000 description 4
- BSUPFYRQXCQGLJ-UHFFFAOYSA-N Ruscogenin Natural products CC1CCC2(OC1)OC3C(O)C4C5CC=C6CC(O)CC(O)C6(C)C5CCC4(C)C3C2C BSUPFYRQXCQGLJ-UHFFFAOYSA-N 0.000 description 4
- 244000261559 Smilax china Species 0.000 description 4
- 235000000485 Smilax china Nutrition 0.000 description 4
- 240000009022 Smilax rotundifolia Species 0.000 description 4
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 4
- 229940093265 berberine Drugs 0.000 description 4
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 4
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- QMQIQBOGXYYATH-UHFFFAOYSA-N epiruscogenin Natural products CC1C(C2(CCC3C4(C)C(O)CC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 QMQIQBOGXYYATH-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000021050 feed intake Nutrition 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 4
- 229960004949 glycyrrhizic acid Drugs 0.000 description 4
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 4
- 235000019410 glycyrrhizin Nutrition 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 229940109990 ruscogenin Drugs 0.000 description 4
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical group C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 3
- 241000223924 Eimeria Species 0.000 description 3
- 208000015220 Febrile disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 3
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 3
- 206010041235 Snoring Diseases 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 3
- 229960003321 baicalin Drugs 0.000 description 3
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 3
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- CZRGNFVQUYWGKP-UHFFFAOYSA-N 5-hydroxy-2-(2-hydroxyphenyl)-7,8-dimethoxychromen-4-one Chemical compound COC=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1O CZRGNFVQUYWGKP-UHFFFAOYSA-N 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- 239000003390 Chinese drug Substances 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 description 2
- 206010011703 Cyanosis Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 2
- MXTLAHSTUOXGQF-UHFFFAOYSA-O Jatrorrhizine Chemical compound COC1=CC=C2C=C3C(C=C(C(=C4)O)OC)=C4CC[N+]3=CC2=C1OC MXTLAHSTUOXGQF-UHFFFAOYSA-O 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 241000222640 Polyporus Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- VQQVWGVXDIPORV-UHFFFAOYSA-N Tryptanthrine Chemical compound C1=CC=C2C(=O)N3C4=CC=CC=C4C(=O)C3=NC2=C1 VQQVWGVXDIPORV-UHFFFAOYSA-N 0.000 description 2
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000004056 anthraquinones Chemical class 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 2
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 2
- KZJWDPNRJALLNS-FBZNIEFRSA-N clionasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-FBZNIEFRSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- XYHOBCMEDLZUMP-UHFFFAOYSA-N coptisine Chemical group C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 XYHOBCMEDLZUMP-UHFFFAOYSA-N 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- XIRNKXNNONJFQO-UHFFFAOYSA-N ethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC XIRNKXNNONJFQO-UHFFFAOYSA-N 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229940025878 hesperidin Drugs 0.000 description 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 229940097275 indigo Drugs 0.000 description 2
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 2
- 235000008718 isoliquiritigenin Nutrition 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical group CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- YRCWQPVGYLYSOX-UHFFFAOYSA-N synephrine Chemical compound CNCC(O)C1=CC=C(O)C=C1 YRCWQPVGYLYSOX-UHFFFAOYSA-N 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- FWCXELAAYFYCSR-XTOHQWFCSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S,15S,16R,18R)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-15,16-diol Chemical compound C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@H]([C@H](C[C@]5(C)[C@H]4CC[C@]23C)O)O)O[C@]11CC[C@H](C)CO1 FWCXELAAYFYCSR-XTOHQWFCSA-N 0.000 description 1
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- 125000000545 (4R)-limonene group Chemical group 0.000 description 1
- SQEBMLCQNJOCBG-HVHJFMEUSA-N (5s)-3-(hydroxymethyl)-5-methoxy-4-methyl-5-[(e)-2-phenylethenyl]furan-2-one Chemical compound C=1C=CC=CC=1/C=C/[C@]1(OC)OC(=O)C(CO)=C1C SQEBMLCQNJOCBG-HVHJFMEUSA-N 0.000 description 1
- 239000001149 (9Z,12Z)-octadeca-9,12-dienoate Substances 0.000 description 1
- WTTJVINHCBCLGX-UHFFFAOYSA-N (9trans,12cis)-methyl linoleate Natural products CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- YLRXAIKMLINXQY-ZDUSSCGKSA-O (S)-magnoflorine Chemical compound C1=C(OC)C(O)=C2C3=C(O)C(OC)=CC=C3C[C@@H]3[N+](C)(C)CCC1=C23 YLRXAIKMLINXQY-ZDUSSCGKSA-O 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- CPGCVOVWHCWVTP-LJAQVGFWSA-N (S)-nonacosan-10-ol Chemical compound CCCCCCCCCCCCCCCCCCC[C@@H](O)CCCCCCCCC CPGCVOVWHCWVTP-LJAQVGFWSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- LNJCGNRKWOHFFV-UHFFFAOYSA-N 3-(2-hydroxyethylsulfanyl)propanenitrile Chemical compound OCCSCCC#N LNJCGNRKWOHFFV-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- HPVWWHYNAAZHQR-UHFFFAOYSA-N 3-O-beta-D-glucopyranosyl platycodigenin Natural products CC1(C)CCC2(C(O)CC3(C)C(=CCC4C5(C)CC(O)C(OC6OC(CO)C(O)C(O)C6O)C(CO)(CO)C5CCC34C)C2C1)C(=O)O HPVWWHYNAAZHQR-UHFFFAOYSA-N 0.000 description 1
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241001533384 Circovirus Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000037803 Coptis deltoidea Species 0.000 description 1
- GQEVCHQXWPWARL-UHFFFAOYSA-N Couroupitine A Natural products N1=CC=CC2=CC(=O)N3C4=CC=CC=C4C(=O)C3=C21 GQEVCHQXWPWARL-UHFFFAOYSA-N 0.000 description 1
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- XMGQYMWWDOXHJM-JTQLQIEISA-N D-limonene Natural products CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- FBMORZZOJSDNRQ-UHFFFAOYSA-N Demethoxy,B,HCl-Adriamycin Natural products C1C2C(=C)CCCC2(C)CC2(O)C1=C(C)C(=O)O2 FBMORZZOJSDNRQ-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- FWCXELAAYFYCSR-UHFFFAOYSA-N Episamogenin Natural products CC1C(C2(CCC3C4(C)CC(O)C(O)CC4CCC3C2C2)C)C2OC11CCC(C)CO1 FWCXELAAYFYCSR-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000606807 Glaesserella parasuis Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000827798 Hemerocallis citrina Species 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- YNWXJFQOCHMPCK-UHFFFAOYSA-N Isoliquiritin Natural products OC1C(O)C(O)C(CO)OC1OC(C=C1)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O YNWXJFQOCHMPCK-UHFFFAOYSA-N 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 description 1
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- KYEAXNAYHSCLMT-CVVGWEDFSA-N Magnoflorine Natural products C[C@H]1OC=C2[C@@H]3[C@@H]1CN4CCc5c([nH]c6ccccc56)[C@@H]4[C@@H]3OC2=O KYEAXNAYHSCLMT-CVVGWEDFSA-N 0.000 description 1
- PKIXXJPMNDDDOS-UHFFFAOYSA-N Methyl linoleate Natural products CCCCC=CCCC=CCCCCCCCC(=O)OC PKIXXJPMNDDDOS-UHFFFAOYSA-N 0.000 description 1
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- MAYJEFRPIKEYBL-OASIGRBWSA-N Obacunone Chemical compound C=1([C@@H]2OC(=O)[C@H]3O[C@@]43[C@]3(C)C(=O)C[C@H]5C(C)(C)OC(=O)C=C[C@]5(C)[C@H]3CC[C@]42C)C=COC=1 MAYJEFRPIKEYBL-OASIGRBWSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- HFNGSIBHHMFWQB-UHFFFAOYSA-N Platycogenic acid A Natural products C1C(O)C(O)C(CO)(C(O)=O)C2CCC3(C)C4(C)CC(O)C5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C HFNGSIBHHMFWQB-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- HKOIDIVCPUDLBS-UHFFFAOYSA-N Skullcapflavone II Natural products Oc1cccc(O)c1C2=CC(=O)c3c(O)c(O)c(O)c(O)c3O2 HKOIDIVCPUDLBS-UHFFFAOYSA-N 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- KGGGRGBDMBZXKF-UHFFFAOYSA-N Virganreagenin G Natural products C1C(O)C(O)C(C)(CO)C2CCC3(C)C4(C)CC(O)C5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C KGGGRGBDMBZXKF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- LNOHXHDWGCMVCO-UHFFFAOYSA-N Wogonoside Natural products C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1OC1OC(C(O)=O)C(O)C(O)C1O LNOHXHDWGCMVCO-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001944 accentuation Effects 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Chemical class CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- CPGCVOVWHCWVTP-UHFFFAOYSA-N celidoniol Natural products CCCCCCCCCCCCCCCCCCCC(O)CCCCCCCCC CPGCVOVWHCWVTP-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- YYFOFDHQVIODOQ-UHFFFAOYSA-O columbamine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)O)OC)CC3)[N+]3=CC2=C1OC YYFOFDHQVIODOQ-UHFFFAOYSA-O 0.000 description 1
- CYOURJWVXZHEPP-UHFFFAOYSA-N columbamine Natural products COc1cc2CCN3Cc4c(OC)c(OC)ccc4C=C3c2cc1O CYOURJWVXZHEPP-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008011 embryonic death Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229940067592 ethyl palmitate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 description 1
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- YNWXJFQOCHMPCK-LXGDFETPSA-N isoliquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O YNWXJFQOCHMPCK-LXGDFETPSA-N 0.000 description 1
- JUTMAMXOAOYKHT-UHFFFAOYSA-N karrikinolide Natural products C1=COC=C2OC(=O)C(C)=C21 JUTMAMXOAOYKHT-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- GGWMNTNDTRKETA-UHFFFAOYSA-N licoricone Chemical compound COC1=C(CC=C(C)C)C(OC)=CC(O)=C1C1=COC2=CC(O)=CC=C2C1=O GGWMNTNDTRKETA-UHFFFAOYSA-N 0.000 description 1
- GYCKPTRFNFHGGO-UHFFFAOYSA-N licorinone Natural products COc1cc(O)c(C2=COc3cc(O)cc(O)c3C2=O)c(OC)c1CC=C(C)C GYCKPTRFNFHGGO-UHFFFAOYSA-N 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 1
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 229940105623 neo-synephrine Drugs 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- VSLDMVSILHVDSR-UHFFFAOYSA-N obacunone Natural products CC1(C)OC(=O)C=CC2(C)C1CC(=O)C3(C)C2CCC4(C)C(OC(=O)C5OC345)c6occc6 VSLDMVSILHVDSR-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003684 oxedrine Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000157 polyfructose Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- QKFAFSGJTMHRRY-FVDOMRANSA-M potassium;[(z)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanylbut-3-enylideneamino] sulfate Chemical compound [K+].OC[C@H]1O[C@@H](S\C(CC=C)=N/OS([O-])(=O)=O)[C@H](O)[C@@H](O)[C@@H]1O QKFAFSGJTMHRRY-FVDOMRANSA-M 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- OILHVNROWDFZDW-UHFFFAOYSA-N prosapogenin Natural products CC1(C)CCC2(C(O)CC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6O)C(C)(C=O)C5CCC34C)C2C1)C(=O)O OILHVNROWDFZDW-UHFFFAOYSA-N 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- GMQFOKBGMKVUQZ-UHFFFAOYSA-N scullcapflavone II Chemical compound COC1=CC=CC(O)=C1C1=CC(=O)C2=C(O)C(OC)=C(OC)C(OC)=C2O1 GMQFOKBGMKVUQZ-UHFFFAOYSA-N 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000012153 swine disease Diseases 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 1
- LNOHXHDWGCMVCO-NTKSAMNMSA-N wogonin 7-O-beta-D-glucuronide Chemical compound C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LNOHXHDWGCMVCO-NTKSAMNMSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及一种治疗猪高热病的中药组合物,原料药组分如下:板蓝根、金银花、黄连、黄芩、桔梗、黄芪、陈皮、石膏、知母、玄参、白术、淡竹叶、甘草。本发明制备的治疗猪高热病的中药组合物对防治猪高热病具有确切疗效,且将有可能取代饲料中添加的抗高热病药及其他抗生素,为解决肉猪产品中的药物残留问题提供了可能。
Description
技术领域
本发明涉及一种治疗猪高热病的中药组合物,属于兽药技术领域。
背景技术
从2006年5月份开始,我国华南地区的不少猪场,暴发了一种急性、热性,高致病性和致死性的高热病。该病危害严重,具有传播区域广、传播速度快、死亡率高、治愈率低等特点,造成猪只大量死亡,并逐渐扩散和蔓延到我国的大部分地区。国务院和农业部高度重视高热病,农业部先后两次向联合国粮农组织(FAO)、世界动物卫生组织(OIE)和我国的港澳台地区通报了有关情况。
高热病从2006年开始出现至今,一直是危害养猪业的主要疾病,没有更好的解决方法和预防措施。已经造成大量的猪发病死亡,许多养猪场倒闭,给养猪业带来了不可估量的损失,严重影响了我国养猪业的发展,重创了农民养猪的积极性,给养猪者带来了巨大的经济损失。控制和预防高热病是养猪业健康发展必须解决的问题。然而,目前由于对高热病的病因仍然是一个有争论的问题。按西医的理论根本无从下手,没有更好的解决方法。临床上不用西药治疗还好,一治反而死亡更快,死亡率更高。
猪高热病是由免疫系统被抑制后,失去正常的免疫功能,感染蓝耳病病毒等其他病毒和细菌、寄生虫、真菌、霉菌、毒素其多病原混合或继发感染引起的急性、热性,高致病性和高致死性的传染性疾病。高热病具有疫情流行区域广,疫情传播速度快的特点。疫情各个季节均可发生,不仅发生在气温较高的夏季,而且在春、秋、冬季均可发生。不同日龄猪群均可发病。发病猪场猪只以体温升高为主要特征,患病猪死亡严重,大部分发病猪场患猪发病率在50%以上,死亡率高达20%~80%,甚至接近100%。饲养管理不善、从场外购进猪苗饲养、猪舍通风不良、隔热效果差、饲养密度高、栏舍低矮、饲料质量较差、不重视霉菌毒素危害的猪场更容易发病。使大部分发病猪场损失惨重。许多猪场病死猪同时存在多种病原,也有个别猪场以2~3种病原为主。
中国专利文献CN 102188601A(申请号201110108819.6)公开了一种治疗猪病混合感染的中药散剂,是一种新混感通治散剂。该散剂既能清热解毒,滋阴凉血,清卫透营,避秽止惊为治疗原则,又能激活机体的免疫系统。其内容是纯天然型中药组成。有下述成份组成:贝母、猪苓、黄芩、生地黄、水牛角、黄连、栀子、知母、连翘、丹参、金银花、板蓝根、白花蛇舌草的13味天然中药组成。本发明的新混感通治散剂的制作方法:将上述的成份原料,洗净、晾干,并按照上述成份的原料混匀,采用超微粉碎,成为超微粉末,或切碎并碾磨成200目以上粉末,即制成。
发明内容
本发明针对现有技术的不足,提供一种治疗猪高热病的中药组合物。
一种治疗猪高热病的中药组合物,原料药组分如下,均为重量份:
板蓝根80~85份、金银花80~85份、黄连75~80份、黄芩75~80份、桔梗70~75份、黄芪70~75份、陈皮65~75份、石膏60~70份、知母60~65份、玄参55~60份、白术55~60份、淡竹叶50~55份、甘草45~50份。
根据本发明优选的,原料药组分如下,均为重量份:
板蓝根82份、金银花82份、黄连78份、黄芩78份、桔梗72份、黄芪72份、陈皮70份、石膏65份、知母62份、玄参58份、白术58份、淡竹叶52份、甘草48份。
一种治疗猪高热病的中药口服液的制备方法,包括如下步骤:
(1)将上述黄芪与水混合,料水质量比为1:(6~10),浸泡0.8~1.2h,加热至沸腾,保持微沸1.2~1.8h,过滤,制得一次黄芪药液,药渣与水混合,料水质量比为1:(6~10),加热至沸腾,保持微沸1.2~1.8h,过滤,制得二次黄芪药液,合并一次黄芪药液和二次黄芪药液,浓缩,制得黄芪药液;
(2)将剩余原料药与水混合,料水质量比为1:(6~10),浸泡0.4~0.6h,加热至沸腾,保持微沸1.2~1.8h,过滤,制得一次剩余原料药药液,药渣与水混合,料水质量比为1:(6~10),加热至沸腾,保持微沸0.8~1.2h,过滤,制得二次剩余原料药药液,合并一次剩余原料药药液和二次剩余原料药药液,浓缩,制得剩余原料药药液;
(3)合并步骤(1)制得的黄芪药液与步骤(2)制得的剩余原料药药液,调pH至6.8~7.2,经离心,收集上清液,制得治疗猪高热病的中药口服液。
根据本发明优选的,所述步骤(1)中,水的pH值为7;所述步骤(2)中,水的pH值为4.8~5.2,pH调节剂为盐酸。
根据本发明优选的,所述步骤(1)中,浓缩至每毫升黄芪药液经干燥至恒重后,质量为0.8~1.2克。
根据本发明优选的,所述步骤(2)中,浓缩至每毫升剩余原料药药液经干燥至恒重后,质量为1.8~2.2克。
根据本发明优选的,所述步骤(3)中,pH调节剂为氢氧化钠。
根据本发明优选的,所述步骤(3)中,离心为在3000r/min的条件下离心15min。
药理分析
板蓝根:主要成分有靛蓝,靛玉红,蒽醌类、β-谷甾醇,γ-谷甾醇以及多种氨基酸包括精氨酸,谷氨酸,酪氨酸,脯氨酸,缬氨酸,γ-氨基丁酸,RS-告伊春。另外,还含黑芥子甙,靛甙,色胺酮,1-硫氰酸-2-羟基丁-3-烯,腺甙,棕榈酸,蔗糖和含有12%氨基酸的蛋白多糖。板蓝根性味苦寒,归心、胃经,具有清热解毒,凉血利咽的功效。
金银花:含绿原酸,异绿原酸,白果醇,β-谷甾醇,豆甾醇,β-谷甾醇-D-葡萄糖甙,豆甾醇-D-葡萄糖甙;还含挥发油其成分有芳樟醇,左旋-顺三甲基-2-乙烯基-5-羟基-四氢吡喃,棕榈酸乙酯,1,1-联二环已烷,亚油酸甲酯,苯甲醇,苯乙醇等数十种。金银花性味甘寒,归肺、心、胃经。具有清热解毒,疏散风热的功效。
黄连:黄连根茎含多种生物碱,主要是小檗碱,又称黄连素约为5%~8%,其次为黄连碱、甲基黄连碱、掌叶防己碱、药根碱、非洲防己碱。尚含黄柏酮、黄柏内酯、木兰花碱、阿魏酸等。叶含小檗碱1.4%~2.8%。此外,黄连中还含有多种微量元素。从三角叶黄连中分离鉴定了黄连碱、小檗碱、掌叶防己碱和药根碱。黄连性味苦寒,归心、脾、胃、肝、胆、大肠经。具有清热燥湿,泻火解毒功效。
黄芩:含多种黄芩甙,黄芩素,汉黄芩甙,汉黄芩素,7-甲氧基黄芩素,7-甲氧基去甲基汉黄芩素,黄芩黄酮Ⅰ,黄芩黄酮II等。主要功效有清热燥湿,泻火解毒,止血,安胎,降血压。
桔梗:为桔梗科植物桔梗的干燥根部,味苦、辛,性微温,入肺经。根含多种皂甙,水解后分得的皂甙元有:桔梗皂甙元以及少量的新远志酸、桔梗酸A、B、C。此外,从皂甙中尚分得前皂甙元,为次级甙,是桔梗皂甙元-3-0-β-葡萄糖甙。由总皂甙中分得桔梗皂甙C,水解生成桔梗皂甙元和葡萄糖、木糖、鼠李糖、阿拉伯糖(2:1:1:1)。根另含α-菠菜甾醇、α-菠菜甾醇-β-D-葡萄糖甙、桦皮醇、桔梗聚果糖、氨基酸。功效:宣肺、祛痰、利咽、排脓、利五脏、补气血、补五劳、养气。
黄芪:主要含有黄芪皂苷类、黄芪多糖类、黄酮类、氨基酸类及少量微量元素。因主要成分均可溶于水,所以可以采取煎煮提取有效成分。
陈皮:陈皮含挥发油1.5%(压榨法)至2%(蒸馏法),油中主要成分为D-柠檬烯等,另含黄酮类成分橙皮甙、新橙皮甙、柑橘素、二氢川陈皮素及5-去甲二氢川陈皮素;又报道川陈皮含橙皮甙约8.4%,川陈皮素约0.15%。另含辛弗林(对羟福林)0.28%-2.54%。性温,味辛、味苦。入脾经、胃经、肺经。功效:理气健脾,调中,燥湿,化痰。
石膏:石膏是一种矿物名,主要化学成分是硫酸钙(CaSO4)。辛、甘,大寒。具有解肌清热,除烦止渴、清热解毒、泻火的功效。
知母:根茎含多种皂甙,其皂甙元为菝葜皂甙元,其中知母皂甙A-Ⅰ为菝葜皂甙元和1分子半乳糖结合的甙,知母皂甙A-Ⅲ为知母皂甙A-Ⅰ和1分子葡萄糖结合的甙,知母皂甙B-Ⅰ为菝葜皂甙元与1分子半乳糖和2分子葡萄糖结合的甙,知母皂甙A-Ⅱ、A-Ⅳ、B-Ⅱ的结构尚不明;还有伪原知母皂甙A-Ⅲ。鲜根茎所含皂甙,其皂甙元除菝葜皂甙元外,还分离得马尔可皂甙元、新支芷皂甙元。此外,尚含胆碱、烟酸、泛酸、芒果甙。知母苦、甘,寒,归肺、胃、肾经。功效:清热泻火,生津润燥。
玄参:玄参含生物碱、糖类、甾醇、氨基酸、脂肪酸、挥发油、胡萝卜素和维生素A类物质.味甘、苦、咸;性微寒。归肺,胃,肾经。具有清热凉血,泻火解毒,滋阴的功效。
白术:主要成分为苍术醇、苍术酮等,并含有维生素A。根茎含挥发油约1.4%,油中含苍术酮,尚含白术内酯甲、乙、芹烷二烯酮、β-芹油烯、桉树萜;另含氧香豆素类、糖类及树脂等。性味苦、甘,温,归脾、胃经。功效:补脾,益胃,燥湿,和中,安胎。
淡竹叶:竹叶中含有大量的黄酮类化合物和生物活性多糖及其他有效成分,如酚酸类化合物、蒽醌类化合物、萜类内酯、特种氨基酸和活性肤、锰、锌、硒等微量元素。竹叶中所含的功能因子主要是黄酮糖苷和香豆素类内酯。性味甘淡,寒,无毒。入心经、肾经。具有甘淡渗利,性寒清降,善导心与小肠之火下行而利尿通淋的功效。
甘草:主要含甘草甜素,系甘草酸的钙盐,钾盐。甘草酸水解后产生葡萄糖醛酸,甘草次酸。还含黄酮类化合物甘草甙,甘草甙元,异甘草甙,异甘草甙元及甘草利酮,芒柄黄花素,甘草素,异甘草素,树脂等。因主要成分均可溶于水,所以可以采取煎煮提取有效成分。
本发明所述中药组合物是在中医传统理论《伤寒论》和《温病论》的指导下,对高热病进行卫气营血辨证和六经辩证,结合中药的药性和归经,在传统方剂的基础上进行调整而成。方中板蓝根、金银花清热解毒、疏风散热共为君药;黄连、黄芩、桔梗和黄芪泻火解毒、清热燥湿、宣肺、补养气血共为臣药;陈皮、石膏、知母、玄参,白术清热泻火、理气健脾、滋补脾胃共为使药;淡竹叶、甘草导火下行,调和诸药为使药。以上诸药共奏清瘟解毒、泻火凉血、滋补阴津之功。
有益效果
本发明制备的治疗猪高热病的中药组合物对防治猪高热病具有确切疗效,且将有可能取代饲料中添加的抗高热病药及其他抗生素,为解决肉猪产品中的药物残留问题提供了可能。
具体实施方式
下面结合实施例对本发明的技术方案做进一步说明,但本发明所保护范围不限于此。
实施例1
一种治疗猪高热病的中药组合物,原料药组分如下,均为重量份:
板蓝根82份、金银花82份、黄连78份、黄芩78份、桔梗72份、黄芪72份、陈皮70份、石膏65份、知母62份、玄参58份、白术58份、淡竹叶52份、甘草48份。
将上述治疗鸡球虫的中药组合物制备成中药口服液的方法,包括如下步骤:
(1)将上述黄芪与水混合,水的pH值为7,料水质量比为1:8,浸泡1h,加热至沸腾,保持微沸1.5h,过滤,制得一次黄芪药液,药渣与水混合,料水质量比为1:8,加热至沸腾,保持微沸1.5h,过滤,制得二次黄芪药液,合并一次黄芪药液和二次黄芪药液,浓缩,制得黄芪药液;
(2)将剩余原料药与水混合,水的pH值为5,料水质量比为1:8,浸泡0.5h,加热至沸腾,保持微沸1.5h,过滤,制得一次剩余原料药药液,药渣与水混合,料水质量比为1:8,加热至沸腾,保持微沸1h,过滤,制得二次剩余原料药药液,合并一次剩余原料药药液和二次剩余原料药药液,浓缩,制得剩余原料药药液;
(3)合并步骤(1)制得的黄芪药液与步骤(2)制得的剩余原料药药液,调pH至7,经3000r/min的条件下离心15min,收集上清液,制得治疗猪高热病的中药口服液。
所述步骤(2)中,pH调节剂为盐酸。
所述步骤(1)中,浓缩至每毫升黄芪药液经干燥至恒重后,质量为1克。
所述步骤(2)中,浓缩至每毫升剩余原料药药液经干燥至恒重后,质量为2克。
所述步骤(3)中,pH调节剂为氢氧化钠。
实施例2
一种治疗猪高热病的中药组合物,原料药组分如下,均为重量份:
板蓝根80份、金银花85份、黄连75份、黄芩80份、桔梗70份、黄芪75份、陈皮65份、石膏70份、知母60份、玄参60份、白术55份、淡竹叶55份、甘草45份。
将上述治疗鸡球虫的中药组合物制备成中药口服液的方法,包括如下步骤:
(1)将上述黄芪与水混合,水的pH值为7,料水质量比为1:6,浸泡1h,加热至沸腾,保持微沸1.2h,过滤,制得一次黄芪药液,药渣与水混合,料水质量比为1:6,加热至沸腾,保持微沸1.2h,过滤,制得二次黄芪药液,合并一次黄芪药液和二次黄芪药液,浓缩,制得黄芪药液;
(2)将剩余原料药与水混合,水的pH值为5,料水质量比为1:6,浸泡0.4h,加热至沸腾,保持微沸1.2h,过滤,制得一次剩余原料药药液,药渣与水混合,料水质量比为1:6,加热至沸腾,保持微沸0.8h,过滤,制得二次剩余原料药药液,合并一次剩余原料药药液和二次剩余原料药药液,浓缩,制得剩余原料药药液;
(3)合并步骤(1)制得的黄芪药液与步骤(2)制得的剩余原料药药液,调pH至6.8,经3000r/min的条件下离心15min,收集上清液,制得治疗猪高热病的中药口服液。
所述步骤(2)中,pH调节剂为盐酸。
所述步骤(1)中,浓缩至每毫升黄芪药液经干燥至恒重后,质量为1.2克。
所述步骤(2)中,浓缩至每毫升剩余原料药药液经干燥至恒重后,质量为2.2克。
所述步骤(3)中,pH调节剂为氢氧化钠。
实施例3
一种治疗猪高热病的中药组合物,原料药组分如下,均为重量份:
板蓝根85份、金银花80份、黄连80份、黄芩75份、桔梗75份、黄芪70份、陈皮75份、石膏60份、知母65份、玄参55份、白术60份、淡竹叶50份、甘草50份。
将上述治疗鸡球虫的中药组合物制备成中药口服液的方法,包括如下步骤:
(1)将上述黄芪与水混合,水的pH值为7,料水质量比为1:10,浸泡1.2h,加热至沸腾,保持微沸1.8h,过滤,制得一次黄芪药液,药渣与水混合,料水质量比为1:10,加热至沸腾,保持微沸1.8h,过滤,制得二次黄芪药液,合并一次黄芪药液和二次黄芪药液,浓缩,制得黄芪药液;
(2)将剩余原料药与水混合,水的pH值为5,料水质量比为1:10,浸泡0.6h,加热至沸腾,保持微沸1.8h,过滤,制得一次剩余原料药药液,药渣与水混合,料水质量比为1:10,加热至沸腾,保持微沸1.2h,过滤,制得二次剩余原料药药液,合并一次剩余原料药药液和二次剩余原料药药液,浓缩,制得剩余原料药药液;
(3)合并步骤(1)制得的黄芪药液与步骤(2)制得的剩余原料药药液,调pH至7.2,经3000r/min的条件下离心15min,收集上清液,制得治疗猪高热病的中药口服液。
所述步骤(2)中,pH调节剂为盐酸。
所述步骤(1)中,浓缩至每毫升黄芪药液经干燥至恒重后,质量为0.8克。
所述步骤(2)中,浓缩至每毫升剩余原料药药液经干燥至恒重后,质量为1.8克。
所述步骤(3)中,pH调节剂为氢氧化钠。
对比例1
一种中药组合物,原料药组分如下,均为重量份:
贝母50g、猪苓40g、黄芩70g、生地黄70g、水牛角80g、黄连70g、栀子80g、知母50g、连翘50g、丹参50g、金银花40g、板蓝根82g和白花蛇舌草25g。
将上述中药组合物制备成中药口服液的方法,包括如下步骤:
将上述原料药与水混合,水的pH值为7,料水质量比为1:8,浸泡1h,加热至沸腾,保持微沸1.5h,过滤,制得一次原料药液,药渣与水混合,料水质量比为1:8,加热至沸腾,保持微沸1.5h,过滤,制得二次原料药液,合并一次原料药液和二次原料药液,浓缩,制得原料药液,经3000r/min的条件下离心15min,收集上清液,制得中药口服液。
所述步骤(1)中,浓缩至每毫升中药口服液经干燥至恒重后,质量为1.5克。
试验例
1.方法
1.1药品和试剂
抗病毒1号,地塞米松,安痛定。
1.2实验动物:选取临床抗生素治疗无效的高热病猪。临床检查患病猪体温高达39.5℃~41.5℃,呼吸困难(腹式呼吸)、精神沉郁、嗜睡、食欲不振,严重者咳嗽、气喘,呼吸频率高达80次/min以上,耳部、腹部和腿部发绀等症状,个别出现抽搐,心音亢进,尿液减少。剖检病猪可见肺充血、出现水肿,局灶性肺炎;有的有胸腔积液、肺门淋巴结肿大等症状。临床上曾用过多种药物治疗如磺胺嘧啶,青、链霉素等均未见效果。
1.3给药方法:
治疗猪高热病的中药口服液预防组,对于患高热病病猪的周边健康猪进行施用实施例1制备的治疗猪高热病的中药口服液进行预防治疗,按照体积百分比0.2%的比例混入饮水中给药,连用5-7天。
治疗猪高热病的中药口服液治疗组,对病情较严重,无食欲、饮欲的病猪用胃管给药进行施用实施例1制备的治疗猪高热病的中药口服液进行治疗,按照体积百分比0.3%的比例混入饮水中给药,连用5-7天。
西药治疗组,用抗病毒1号,地米和安痛定进行治疗,按照说明书剂量使用,连用5-7天。
西药预防组,对于患高热病病猪的周边健康猪使用抗病毒1号,地米和安痛定进行预防治疗,按照说明书剂量使用,连用3-5天。
对比例治疗组,对病情较严重,无食欲、饮欲的病猪用胃管给药进行施用对比例1制备的中药口服液进行治疗,按照体积百分比0.3%的比例混入饮水中给药,连用5-7天。
对比例预防组,对于患高热病病猪的周边健康猪使用对比例1制备的中药口服液进行预防,按照体积百分比0.2%的比例混入饮水中给药,连用5-7天。
1.4效果判定标准及观察方法:
1.4.1预防效果判定标准:(1)有效:生猪完全没有发病或发病后症状较轻,在观察期内自行康复的;(2)显效:生猪完全没有发病;(3)无效:生猪发病,且在观察期内死亡或没有自行康复的。
1.4.2治疗效果判定标准:(1)有效:病猪体温、体色、精神、食欲逐步恢复正常;大便干结程度逐步改善或病猪逐渐痊愈,观察期内未复发的;(2)治愈:病猪体温、体色、粪便、精神、食欲恢复正常,且不复发的;(3)无效:经用药后,病猪症状并未缓解,甚至加重死亡。
1.4.3观察方法:指定专人进行治疗试验,自投药之日起连续观察6d,每天上午、下午各观察1次,每天定时测定体温,及时做好观察记录。观察猪只的精神、采食、体温、呼吸、皮肤和耳朵颜色及死亡等情况,按以下标准计算死亡率、治愈率、有效率。试验期间保持圈舍干燥、清洁、通风,饲喂、饮水和饲养管理按常规方法进行,尽可能保持一致。
死亡率凡在试验期间,出现附高热病的典型症状而死亡,尸体剖检有特征性病变,即可判定为感染死亡,根据死亡猪数计算死亡率。
治愈率凡在试验期间,经给药后精神状态和食欲恢复正常,不再出现发热等症状,均属治愈,根据治愈数计算治愈率。
有效率用药后,猪的精神、食欲、呼吸、体温有明显好转,均判为有效,据此计算有效率,其余均为疗效不明显或无效。
1.5数据的分析处理
对试验结果进行生物统计学分析,对发病率、致死率采用X2检验;其余计量资料采用T检验比较实验组与西药对照组的显著性差异。
2、结果
2.1体温检测:体温检测结果如下表,由表可见,经药物治疗后动物的体温都发生了变化。所有药物治疗组在用药后体温都发生了下降,治疗猪高热病的中药口服液治疗组体温下降较西药治疗组慢,但是不反复。西药治疗组下降较快,但是会发生反复。在第三天体温基本上都恢复正常。治疗猪高热病的中药口服液治疗组在第五天后精神状态、采食等完全恢复正常,而西药治疗组在头三天体温降到正常,而后在四天部分猪又体温上升,且食欲及精神沉郁等方面无明显改善。
表1动物体温治疗过程中的变化(单位:℃)
2.2实验疗效:用治疗猪高热病的中药口服液治疗1500例猪高热病例均取得较好的效果。累计1238头患猪经治疗后恢复正常,治愈率达82.5%。通过对死亡率、治愈率、有效率统计(见表2)表明,实验组和对照组差异显著。治疗猪高热病的中药口服液治疗组治愈率和总有效率均显著高于西药治疗对照组(P<0.05),表明治疗猪高热病的中药口服液治疗组对猪高热病有疗效。经临床观察,猪群用药后第2d,发热的患猪没有增加,少数患猪开始少量采食。用药后第3d,发热的患猪开始减少,患猪的一些病症开始改善(如皮肤没有那么红、尿颜色变淡、精神好转、采食量增加)。用药后第4d,多数患猪恢复正常食欲,皮肤颜色逐渐恢复正常,精神进一步好转。用药后第5d,除少量患猪皮肤发绀外,绝大多数恢复正常食欲。治疗猪高热病的对比例治疗中药组治愈率和总有效率均高于西药治疗对照组,但低于治疗猪高热病的中药口服液治疗组,证实治疗猪高热病的对比例治疗中药组对猪高热病的疗效比西药组好但不如中药试验组。服用治疗猪高热病的中药口服液后病情很快得到控制,而对比例治疗组的病情恢复的慢,治愈率和总有效率分别是31.21%,35.0%,死亡率达24.0%,仅次于西药对照组。对比例治疗组和西药治疗对照组症状恢复都比较缓慢,10-15天也不能恢复到原来的采食量,呼噜、咳嗽症状比治疗组严重的多。
治疗猪高热病的中药口服液组的预防有效率和治疗总有效率分别是96%和89.0%。较西药治疗组治愈率31.7.6%,提高50.8%;治疗猪高热病的中药口服液的病死率显著低于西药对照组(P<0.01),且症状恢复较快,一般5天左右,猪群的整体精神状态好转,采食量基本恢复到发病前的状态,呼噜、咳嗽等症状明显减轻。
治疗猪高热病的对比例治疗组的预防有效率和治疗总有效率分别是58.2%和35.0%。较西药治疗组治愈率31.7%,提高0.5%;通过实验数据可以看出,对比例组预防和治疗效果远远不如中药口服液试验组,基本接近西药对照组。治疗猪高热病对比例组的病死率显著低于治疗猪高热病的中药口服液组(P<0.01),且症状恢复慢,一般在10-15天左右才能够恢复,猪群的整体精神状态好转,采食量基本恢复到发病前的状态,呼噜、咳嗽等症状明显减轻。
表2各组的治疗效果
表3各组的预防效果
3、讨论
猪高热病是指以蓝耳病为主的猪瘟、伪狂犬病、圆环病毒病、日本乙型脑炎、渗出性皮炎(葡萄球菌病)、支原体肺炎、链球菌病、副猪嗜血杆菌病、霉玉米中毒、附红细胞体病、寄生虫病等引起的病毒或病菌性疾病,应该是在猪体内正常的“菌群平衡”受到破坏后引起的病毒与细菌性疾病的混合感染。当这种混合感染比较轻微时,在母猪生产上仅表现生殖系统功能紊乱,引起胚胎死亡或是流产;当感染严重时,就会出现体温升高,这种体温升高现象可以分为感冒性发热、炎性发热及败血性发热。该病是以高热、粪便发硬呈球状、食欲废绝、皮肤发红为特征的传染病,其发病率在50%以上,死亡率高达50%-100%。
经上述实验表明,中草药治疗猪高热病,方法简单,投喂确实,大规模饲养尤其方便。中草药来源广,取材容易,价格低廉,且疗效高,无有害残留,毒副作用小,不易产生耐药性。瘟疫灵口服液是搜集、提炼、不断优化防治方案,最终获得了一整套成功的防治技术。
实施例1制得的口服液与对比例1制得的口服液中主要药物皆具有清热解毒的作用。实验证实,实施例1制得的口服液组效果明显优于对比例1制得的口服液组,猪高热病属于温热性疾病,临床上会出现体温迅速升高、口渴、喜饮冷水、皮肤潮红、精神萎靡、食少纳呆等症状。该病死亡率高,严重阻碍着养猪业的发展,并且给广大养殖户造成巨大的经济损失。
中医认为:“正气存内,邪不可干;邪之所凑,其气必虚”。在确立温热性疾病的防治法则上一方面驱邪,另外一方面注意固本,正符合中医“治病求本”的根本原则,据此,实施例1制得的口服液配伍在注重驱邪的同时也重用了黄芪、玄参、白术、甘草等补益类中药进行扶正,达到了“祛邪扶正”的目的。对比例1制得的口服液配伍上大量地使用了驱邪药而没有采取“扶正”措施,因此,效果远远不如实施例1制得的口服液。
Claims (8)
1.一种治疗猪高热病的中药组合物,其特征在于,原料药组分如下,均为重量份:
板蓝根80~85份、金银花80~85份、黄连75~80份、黄芩75~80份、桔梗70~75份、黄芪70~75份、陈皮65~75份、石膏60~70份、知母60~65份、玄参55~60份、白术55~60份、淡竹叶50~55份、甘草45~50份。
2.如权利要求1的中药组合物,其特征在于,原料药组分如下,均为重量份:
板蓝根82份、金银花82份、黄连78份、黄芩78份、桔梗72份、黄芪72份、陈皮70份、石膏65份、知母62份、玄参58份、白术58份、淡竹叶52份、甘草48份。
3.一种治疗猪高热病的中药口服液的制备方法,其特征在于,包括如下步骤:
(1)将权利要求1所述的黄芪与水混合,料水质量比为1:(6~10),浸泡0.8~1.2h,加热至沸腾,保持微沸1.2~1.8h,过滤,制得一次黄芪药液,药渣与水混合,料水质量比为1:(6~10),加热至沸腾,保持微沸1.2~1.8h,过滤,制得二次黄芪药液,合并一次黄芪药液和二次黄芪药液,浓缩,制得黄芪药液;
(2)将权利要求1中所述除黄芪外的剩余原料药与水混合,料水质量比为1:(6~10),浸泡0.4~0.6h,加热至沸腾,保持微沸1.2~1.8h,过滤,制得一次剩余原料药药液,药渣与水混合,料水质量比为1:(6~10),加热至沸腾,保持微沸0.8~1.2h,过滤,制得二次剩余原料药药液,合并一次剩余原料药药液和二次剩余原料药药液,浓缩,制得剩余原料药药液;
(3)合并步骤(1)制得的黄芪药液与步骤(2)制得的剩余原料药药液,调pH至6.8~7.2,经离心,收集上清液,制得治疗猪高热病的中药口服液。
4.如权利要求3所述的制备方法,其特征在于,所述步骤(1)中,水的pH值为7;所述步骤(2)中,水的pH值为4.8~5.2,pH调节剂为盐酸。
5.如权利要求3所述的制备方法,其特征在于,所述步骤(1)中,浓缩至每毫升黄芪药液经干燥至恒重后,质量为0.8~1.2克。
6.如权利要求3所述的制备方法,其特征在于,所述步骤(2)中,浓缩至每毫升剩余原料药药液经干燥至恒重后,质量为1.8~2.2克。
7.如权利要求3所述的制备方法,其特征在于,所述步骤(3)中,pH调节剂为氢氧化钠。
8.如权利要求3所述的制备方法,其特征在于,所述步骤(3)中,离心为在3000r/min的条件下离心15min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410658595.XA CN104367874B (zh) | 2014-11-18 | 2014-11-18 | 一种治疗猪高热病的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410658595.XA CN104367874B (zh) | 2014-11-18 | 2014-11-18 | 一种治疗猪高热病的中药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104367874A true CN104367874A (zh) | 2015-02-25 |
CN104367874B CN104367874B (zh) | 2017-10-03 |
Family
ID=52547234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410658595.XA Expired - Fee Related CN104367874B (zh) | 2014-11-18 | 2014-11-18 | 一种治疗猪高热病的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104367874B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104840601A (zh) * | 2015-04-22 | 2015-08-19 | 日照市畜牧站 | 一种防治猪流行性热性病的中药制剂 |
CN104855690A (zh) * | 2015-06-11 | 2015-08-26 | 山东新希望六和集团有限公司 | 一种育成猪配合饲料及其制备方法 |
CN105935418A (zh) * | 2016-04-18 | 2016-09-14 | 六枝特区垄鑫盛泰农业发展有限公司 | 一种治疗猪高热综合症的药物及其制备方法 |
CN107551151A (zh) * | 2017-09-18 | 2018-01-09 | 颍上庆丰农牧发展有限公司 | 一种用于治疗猪高热综合症的注射液及其制备方法 |
CN108096434A (zh) * | 2017-12-05 | 2018-06-01 | 广州白云山宝神动物保健品有限公司 | 一种猪饲料的植物添加剂及其制备方法与应用 |
CN108210587A (zh) * | 2018-04-18 | 2018-06-29 | 聊城大学 | 一种治疗家禽病毒性疾病的中药组合物及其应用 |
CN115414350A (zh) * | 2022-09-22 | 2022-12-02 | 湖北省农业科学院畜牧兽医研究所 | 芒果苷在制备抑制副猪嗜血杆菌药物中的应用 |
-
2014
- 2014-11-18 CN CN201410658595.XA patent/CN104367874B/zh not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
张保平 等: "中草药在防治猪病上的应用", 《今日畜牧兽医》 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104840601A (zh) * | 2015-04-22 | 2015-08-19 | 日照市畜牧站 | 一种防治猪流行性热性病的中药制剂 |
CN104855690A (zh) * | 2015-06-11 | 2015-08-26 | 山东新希望六和集团有限公司 | 一种育成猪配合饲料及其制备方法 |
CN105935418A (zh) * | 2016-04-18 | 2016-09-14 | 六枝特区垄鑫盛泰农业发展有限公司 | 一种治疗猪高热综合症的药物及其制备方法 |
CN107551151A (zh) * | 2017-09-18 | 2018-01-09 | 颍上庆丰农牧发展有限公司 | 一种用于治疗猪高热综合症的注射液及其制备方法 |
CN108096434A (zh) * | 2017-12-05 | 2018-06-01 | 广州白云山宝神动物保健品有限公司 | 一种猪饲料的植物添加剂及其制备方法与应用 |
CN108096434B (zh) * | 2017-12-05 | 2021-03-12 | 广州白云山宝神动物保健品有限公司 | 一种猪饲料的植物添加剂及其制备方法与应用 |
CN108210587A (zh) * | 2018-04-18 | 2018-06-29 | 聊城大学 | 一种治疗家禽病毒性疾病的中药组合物及其应用 |
CN115414350A (zh) * | 2022-09-22 | 2022-12-02 | 湖北省农业科学院畜牧兽医研究所 | 芒果苷在制备抑制副猪嗜血杆菌药物中的应用 |
CN115414350B (zh) * | 2022-09-22 | 2023-08-04 | 湖北省农业科学院畜牧兽医研究所 | 芒果苷在制备抑制副猪嗜血杆菌药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104367874B (zh) | 2017-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104367874A (zh) | 一种治疗猪高热病的中药组合物 | |
CN104256168A (zh) | 一种猪功能性饲料及其制备方法 | |
CN103977368B (zh) | 一种用于治疗风湿寒热所致痹病的中药组合物及其制备方法 | |
CN102846804B (zh) | 治疗淡水鱼嗜水气单胞菌病的中草药制剂及其制备方法 | |
CN104208393B (zh) | 一种用于防治鸡传染性支气管炎的中药组合物及其制备方法 | |
CN104436131A (zh) | 一种用于治疗猪痢疾的药物组合物及其制备方法 | |
CN103800650A (zh) | 一种治疗清肺化痰的中药 | |
CN102846864A (zh) | 一种防治猪传染性萎缩性鼻炎的中药兽药及其制备方法 | |
CN104161977B (zh) | 一种用于防治鸡传染性鼻炎的中药组合物及其制备方法 | |
CN108771754B (zh) | 一种用于治疗产蛋鸡中后期输卵管炎的中药组合物及其制备方法 | |
CN104208339A (zh) | 一种用于治疗畜禽细菌性、病毒性疾病的中药组合物及其制备方法 | |
CN103961614A (zh) | 用于治疗呼吸系统疾病的中药组合物及其制备方法和用途 | |
CN107998280A (zh) | 一种家禽用抗生素替代品及其制备方法与应用 | |
CN105250460A (zh) | 一种治疗兔腹泻的药物组合物及其制备方法 | |
CN104189784A (zh) | 一种用于口疮的中药制剂及其制备方法 | |
CN108210587A (zh) | 一种治疗家禽病毒性疾病的中药组合物及其应用 | |
CN105232959B (zh) | 一种中药组合物 | |
CN104161817B (zh) | 一种用于防治鸡细菌性疾病的复方中药组合物及其制备方法 | |
CN104288722A (zh) | 用于治疗猪传染性胸膜肺炎的药物组合物及其制备方法 | |
CN105327147A (zh) | 用于治疗猪气喘病的药物组合物及其制备方法 | |
CN104873730A (zh) | 一种治疗肝气郁结型急性乳腺炎的中药及制备方法 | |
CN104147399A (zh) | 一种用于猪瘟的药物制剂 | |
CN104474430A (zh) | 一种治疗肝肾阴虚型霉菌性阴道炎的中药及制备方法 | |
CN104208168B (zh) | 一种用于治疗家禽呼吸道感染的复方中药组合物及其制备方法 | |
CN107960535A (zh) | 一种防治肉牛胃肠炎的饲料添加剂及其生产方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171003 |
|
CF01 | Termination of patent right due to non-payment of annual fee |